IFNA2 and neoplasm: Human melanoma tumor cells (A375 and WM1366) were plated at a density of 2 × 105 cells/well on 6 well plates and treated for 48 hours with complete medium supplemented with either 5 × 103 U/mL IFN-α, 35 nM ixazomib, 10 nM bortezomib, or the combination of ixazomib or bortezomib plus IFN-α.